Delayed Onset Anthracycline-Associated Cardiotoxicity Presenting as Acute Decompensated Heart Failure Seven Years After Chemotherapy Completion.
| Autor: | Tran DB; Medicine, Florida International University, Herbert Wertheim College of Medicine, Miami, USA., AlAshi AK; Medicine, Florida International University, Herbert Wertheim College of Medicine, Miami, USA., Hernandez A; Translational Medicine, Florida International University, Herbert Wertheim College of Medicine, Miami, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Aug 05; Vol. 13 (8), pp. e16920. Date of Electronic Publication: 2021 Aug 05 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.16920 |
| Abstrakt: | Anthracyclines are a class of chemotherapeutic agents commonly used to treat a variety of malignancies including leukemias and lymphomas. Cardiotoxicity is a well-known clinical adverse effect of anthracyclines with a diverse range of presentations and manifestations. While the vast majority of cardiotoxicity from anthracyclines presents acutely during or within one year after chemotherapy, they rarely cause long-term effects several years after. Here, we present a case of sudden and delayed onset doxorubicin-associated cardiotoxicity seven years following chemotherapy completion. We review important and evidence-based clinical diagnostic workup and management strategies for atypical anthracycline-associated cardiotoxicity in a young patient with acute decompensated heart failure. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Tran et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|